Who Paid My Doc
Tanya Giese
Nurse Practitioner, Primary Care Williston, ND Nurse Practitioner
NPI 1548997240 CMS profile 11346626
1321 W Dakota Pkwy, Williston, ND 58801
General payments
$124
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Tanya Giese of Williston, ND is reported in the CMS Open Payments database as having received $124 across 6 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 30th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $77 | 4 | |
| 2022 | General | $47 | 2 |
Beside peers
- Tanya Giese
- Nurse Practitioner, Primary Care median
- Middle half of Nurse Practitioner, Primary Care
- National median
In program year 2025, general payments to Tanya Giese were reported at $77. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.
Show as a table
| Year | Tanya Giese | Nurse Practitioner, Primary Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $137 | $39–$445 | $132 |
| 2022 | $47 | $139 | $44–$421 | $149 |
| 2023 | $0 | $163 | $53–$481 | $160 |
| 2024 | $0 | $176 | $54–$511 | $164 |
| 2025 | $77 | $169 | $51–$499 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 95 drugsPart D claims
3,029
Drug cost
$164,740
Branded share of claims
21.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 49 | $29,951 | |
| Ozempic Semaglutide | Brand | 23 | $25,663 | |
| Mounjaro Tirzepatide | Brand | 11 | $19,161 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 21 | $17,035 | |
| Januvia Sitagliptin Phosphate | Brand | 18 | $9,805 | |
| Xarelto Rivaroxaban | Brand | 17 | $9,312 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 12 | $4,923 | |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 14 | $4,184 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 14 | $3,155 | |
| Autoshield Duo Pen Needle Pen Needle,dual Safety,diabetc | Brand | 22 | $2,251 |
The 10 drugs with the highest cost, of 95 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 71 billing codesPaid by Medicare
$52,070
Medicare patients
227
Services billed
1,787
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 47% | |
| Depression | 33% | |
| Diabetes | 27% | |
| Alzheimer's or dementia | 22% | |
| Ischemic heart disease | 20% | |
| Heart failure | 19% | |
| COPD | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90662 | Office | 19 | 19 | $1,397 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
6 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Nurse Practitioner, Primary Care in North Dakota
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Primary Care
Everyone recorded under this specialty, nationwide.
Doctors in North Dakota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.